These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Potential role of tavaborole for the treatment of onychomycosis. Gupta AK; Daigle D Future Microbiol; 2014; 9(11):1243-50. PubMed ID: 25437186 [TBL] [Abstract][Full Text] [Related]
3. Efinaconazole and Tavaborole. Poulakos M; Grace Y; Machin JD; Dorval E J Pharm Pract; 2017 Apr; 30(2):245-255. PubMed ID: 26873506 [TBL] [Abstract][Full Text] [Related]
4. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis. Bueno JG; Martinez C; Zapata B; Sanclemente G; Gallego M; Mesa AC Clin Exp Dermatol; 2010 Aug; 35(6):658-63. PubMed ID: 19874354 [TBL] [Abstract][Full Text] [Related]
5. Characterization of the antimicrobial susceptibility of fungi responsible for onychomycosis in Spain. Zalacain A; Obrador C; Martinez JP; Viñas M; Vinuesa T Med Mycol; 2011 Jul; 49(5):495-9. PubMed ID: 21142899 [TBL] [Abstract][Full Text] [Related]
6. In vitro antifungal activity of sertaconazole nitrate against recent isolates of onychomycosis causative agents. Carrillo-Muñoz AJ; Quindós G; Del Valle O; Santos P; Giusiano G; Guardia C; Eraso E; Ezkurra PA; Tur-Tur C; Hernández-Molina JM J Chemother; 2008 Aug; 20(4):521-3. PubMed ID: 18676237 [No Abstract] [Full Text] [Related]
7. Antifungal susceptibility patterns of yeasts and filamentous fungi isolated from nail infection. Ataides FS; Chaul MH; El Essal FE; Costa CR; Souza LK; Fernandes OF; Silva MR J Eur Acad Dermatol Venereol; 2012 Dec; 26(12):1479-85. PubMed ID: 22049990 [TBL] [Abstract][Full Text] [Related]
8. Tavaborole topical solution, 5% for the treatment of toenail onychomycosis. Zane LT; Plattner J; Chanda S; Coronado D; Merchant T; Alley MR; Gupta AK Drugs Today (Barc); 2015 Oct; 51(10):599-607. PubMed ID: 26583302 [TBL] [Abstract][Full Text] [Related]
9. Tavaborole - a treatment for onychomycosis of the toenails. Gupta AK; Versteeg SG Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1145-52. PubMed ID: 27347905 [TBL] [Abstract][Full Text] [Related]
10. Tavaborole, a novel boron-containing small molecule for the topical treatment of onychomycosis, is noncarcinogenic in 2-year carcinogenicity studies. Ciaravino V; Coronado D; Lanphear C; Shaikh I; Ruddock W; Chanda S Int J Toxicol; 2014; 33(5):419-27. PubMed ID: 25201897 [TBL] [Abstract][Full Text] [Related]
11. Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action. Rosen T; Stein Gold LF Semin Cutan Med Surg; 2016 Mar; 35(3 Suppl 3):S51-5. PubMed ID: 27074700 [TBL] [Abstract][Full Text] [Related]
12. In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species. Gupta AK; Kohli Y; Batra R Med Mycol; 2005 Mar; 43(2):179-85. PubMed ID: 15832561 [TBL] [Abstract][Full Text] [Related]
13. Efinaconazole 10% and Tavaborole 5% Penetrate Across Poly-ureaurethane 16%: Results of In Vitro Release Testing and Clinical Implications of Onychodystrophy in Onychomycosis. Adigun CG; Vlahovic TC; McClellan MB; Thakker KD; Klein RR; Elstrom TA; Ward DB J Drugs Dermatol; 2016 Sep; 15(9):1116-20. PubMed ID: 27602975 [TBL] [Abstract][Full Text] [Related]
14. Examining the Benefits of the Boron-Based Mechanism of Action and Physicochemical Properties of Tavaborole in the Treatment of Onychomycosis. Markinson B; Ghannoum M; Winter T; Rycerz A; Rock F; Gupta AK J Am Podiatr Med Assoc; 2018 Jan; 108(1):12-19. PubMed ID: 29547036 [TBL] [Abstract][Full Text] [Related]
15. Tavaborole for the treatment of onychomycosis. Elewski BE; Tosti A Expert Opin Pharmacother; 2014 Jul; 15(10):1439-48. PubMed ID: 24856836 [TBL] [Abstract][Full Text] [Related]
16. In vitro efficacy of tavaborole topical solution, 5% after penetration through nail polish on ex vivo human fingernails. Gupta AK; Vlahovic TC; Foley KA; Lowe NG; Turner R; Brown M; Hall S J Dermatolog Treat; 2018 Sep; 29(6):633-636. PubMed ID: 29307243 [TBL] [Abstract][Full Text] [Related]
17. Molecular characterization and antifungal activity against non-dermatophyte molds causing onychomycosis. Pakshir K; Kamali M; Nouraei H; Zomorodian K; Motamedi M; Mahmoodi M Sci Rep; 2021 Oct; 11(1):20736. PubMed ID: 34671053 [TBL] [Abstract][Full Text] [Related]
18. In Vitro Nail Penetration and Antifungal Activity of Tavaborole, a Boron-Based Pharmaceutical. Coronado D; Merchant T; Chanda S; Zane LT J Drugs Dermatol; 2015 Jun; 14(6):609-14. PubMed ID: 26091387 [TBL] [Abstract][Full Text] [Related]
19. Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis. Baker SJ; Zhang YK; Akama T; Lau A; Zhou H; Hernandez V; Mao W; Alley MR; Sanders V; Plattner JJ J Med Chem; 2006 Jul; 49(15):4447-50. PubMed ID: 16854048 [TBL] [Abstract][Full Text] [Related]
20. A Mycological and Molecular Epidemiologic Study on Onychomycosis and Determination Halvaee S; Daie-Ghazvini R; Hashemi SJ; Khodavaisy S; Rahimi-Foroushani A; Bakhshi H; Rafat Z; Ardi P; Abastabar M; Zareei M; Borjian-Boroujeni Z; Kamali Sarvestani H Front Cell Infect Microbiol; 2021; 11():693522. PubMed ID: 34336717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]